Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.
The addition of the monoclonal antibody blinatumomab to hyper-CVAD could represent a potential option for extending remission times in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia.
Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.